

Supplementary Materials: Nicotinic Amidoxime Derivate BGP-15, Topical Dosage Formulation and Anti-Inflammatory Effect

Ágota Pető, Dóra Kósa, Ádám Haimhoffer, Pálma Fehér, Zoltán Ujhelyi, Dávid Sinka, Ferenc Fenyvesi, Judit Váradi, Miklós Vecsernyés, Alexandra Gyöngyösi, István Lekli, Péter Szentesi, Annamária Marton, Imre Gombos, Barbara Dukic, László Vigh and Ildikó Bácskay

Table S1. Statistical analysis (*p* values and significance) by comparing the different formulations to each other.

| Composition | <i>p</i> value | Significant | Asterisks |
|--|----------------|-------------|-----------|
| SP50 + BGP-15 vs. SP50 base | 0.0076 | Yes | ** |
| SP70 + BGP-15 vs. SP70 base. | <0.0001 | Yes | **** |
| PS750 + BGP-15 vs. PS750 base | <0.0001 | Yes | **** |
| BGP-15 aqueous sol. vs. SP50 + BGP-15 | 0.0008 | Yes | *** |
| BGP-15 aqueous sol. vs. SP70 + BGP-15 | <0.0001 | Yes | **** |
| BGP-15 aqueous sol. vs. PS750 + BGP-15 | 0.0005 | Yes | *** |

, * and **** indicate statistically significant differences at $p < 0.01$, $p < 0.001$ and $p < 0.0001$, respectively.




Figure S1. Effect of BGP-15 alone and together with surfactants (sucrose esters) on Raw264.7 cells. It appears that BGP-15 treatment resulted some sort of decrease in macrophage activity, but the results are not significantly different.